Pan-India B2B diagnostics chain that runs sample-testing labs for franchisees, hospitals and health platforms.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 159 |
| Reserves | 314 | 374 | 474 | 481 | 474 | 494 | 481 | 426 |
| Borrowings | 12 | 8 | 21 | 23 | 42 | 25 | 25 | 51 |
| Other Liabilities | 90 | 106 | 60 | 74 | 75 | 121 | 121 | 111 |
| Total Liabilities | 469 | 541 | 607 | 632 | 644 | 693 | 680 | 747 |
| AssetsFixed Assets | 269 | 253 | 285 | 294 | 306 | 297 | 301 | 317 |
| CWIP | 5 | 8 | 3 | 2 | 3 | 14 | 3 | 3 |
| Investments | 90 | 126 | 146 | 144 | 162 | 162 | 146 | 177 |
| Other Assets | 105 | 154 | 173 | 192 | 173 | 220 | 230 | 250 |
| Total Assets | 469 | 541 | 607 | 632 | 644 | 693 | 680 | 747 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 100 | 168 | 115 | 113 | 129 | 168 | 191 | 213 |
| Cash from Investing | -12 | 1 | -49 | -24 | -39 | -91 | -53 | -23 |
| Cash from Financing | -94 | -165 | -62 | -89 | -86 | -85 | -130 | -170 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 61 | 158 | 93 | 99 | 88 | 107 | 146 | 198 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (134.6×) and current (48.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 36.6% growth and a 49× exit, ₹541 only delivers your return if you pay ₹1,248. The price is currently baking in 17% growth.
EPS grows 36.6%/yr for 5 years, then fades to 6% over 2, exits at 49×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 36.6% | 15.14 |
| FY28 | 36.6% | 20.67 |
| FY29 | 36.6% | 28.24 |
| FY30 | 36.6% | 38.58 |
| FY31 | 36.6% | 52.70 |
| FY32 | 21.3% ·fade | 63.92 |
| FY33 | 6.0% ·fade | 67.76 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.